Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C

Annals of Internal Medicine

Volumn 124, Issue 12, 1996, Pages 1058-1060

  Chemello, Liliana ^b   Cavalletto, Luisa ^b   Casarin, Carla ^b   Bonetti, Paola ^b   Bernardinello, Elisabetta ^b   Pontisso, Patrizia ^b   Donada, Carlo ^c   Belussi, Fabio ^d   Martinelli, Silio ^e   Alberti, Alfrede ^a,b  

^a Clinica Medica 3   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Divisione Medica Casa   (Italy)

^d Div Malat Infettive Tropicali O   (Italy)

^e OC Cittadella (PD)   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER HISTOLOGY; LONG TERM CARE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; VIREMIA;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHRONIC DISEASE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RNA, VIRAL; TREATMENT OUTCOME; VIREMIA;

EID: 0030317884     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-124-12-199606150-00005     Document Type: Article

References (12)

1. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315:1575-8.
2. Shindo M, Di Bisceglie AM, Cheung L, Shih JW, Cristiano K, Feinstone SM, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 1991;115:700-4.
3. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr. Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant Interferon alfa. A multicenter randomized, controlled trial. N Engl J Med. 1989;321:1501-6.
4. Di Bisceglie AM, Martin P, Kassianides C Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant Interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506-10.
5. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 1993;341:1501-4.
6. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology. 1996;22:700-6.
7. Casarin C Chemello L, Bonetti P, Benvegnù L, De Moliner L, Pontisso P, et al. Comparison of different types and doses of alpha-interferon for treatment of chronic hepatitis C. J Hepatol. 1994:21(Suppl 1):S62.
8. Chemello L, Cavalletto L, Noventa F, Bonetti P, Casarin C, Bemardinello E, et al. Predictors of sustained, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha. J Viral Hepat. 1995;2:91-6.
9. Tisminetzky S, Gerotto M, Pontisso P, Chemello L, Baralle F, Alberti A. Genotype of hepatitis C virus in Italian patients with chronic hepatitis C. Int Hepatol Communications. 1994;2:103-10.
10. Simmonds P, Rose KA, Graham S, Chan SW, McOmish F, Dow BC, et al. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. J Clin Microbiol. 1993;31:1493-503.
11. Lau JY, Mizokami M, Ohno T, Diamond DA, Kniffen J, and Davis GL. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet. 1993;342:1208-9.
12. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology. 1995;21:291-7.